Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of idalopirdine adjunctive to donepezil in mild-moderate Alzheimer's disease
2013-000001-23Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Idalopirdine in Alzheimer's disease (AD), sponsored by Lundbeck. Primary endpoint: Safety: Number of adverse events. Started Jan 2014; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2013-000001-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000001-23.